Eyenovia, Inc.

Ownership Transactions Reported by 24 Insiders

Symbol
EYEN on Nasdaq
Industry
Pharmaceutical Preparations
Location
295 Madison Avenue,, Suite 2400, New York, NY

There are no Buy or Sell transactions made by insiders since 11/25/2024

Eyenovia, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Hyunsu Jung Chief Investment Officer, Director $9.95M Aug 18, 2025
Stuart M. Grant 10%+ Owner $7.2M Jul 2, 2024
David R. Knox Chief Financial Officer $3.6M Sep 29, 2025
Fredric N. Eshelman Director $1.83M Nov 17, 2021
Tsontcho Ianchulev Director $1.54M Apr 21, 2025
Luke Clauson VP Research & Development $771K Jun 16, 2021
Ernest Mario Director $578K Nov 17, 2021
John P. Gandolfo Chief Financial Officer $421K Feb 12, 2024
Michael Geltzeiler Director $385K Aug 18, 2025
Ellen Strahlman Director $376K Aug 18, 2025
Rachel Jacobson Director $373K Aug 18, 2025
Charles E. Mather IV Director $361K Apr 21, 2025
Happy David Walters Director $332K Sep 8, 2025
Ram Palanki Director $283K Apr 21, 2025
Kenneth B. Lee Jr Director $273K Jun 16, 2022
Julia A. Haller Director $226K Jun 16, 2022
Stephen Keith Benjamin Director $220K Jun 16, 2022
Jennifer Clasby VP, Regulatory and Clinical $124K Jun 17, 2021
Curt H. LaBelle Director $115K Nov 17, 2021
Anthony Y. Sun Director $93.8K Nov 17, 2021
Avenue Capital Management II, L.P. 10%+ Owner $36.1K Feb 21, 2025
Michael Rowe Chief Executive Officer, Director $9.41K Jun 13, 2025
Bren Kern Chief Operating Officer $1.5K Apr 21, 2025
Andrew D. Jones Chief Financial Officer Aug 30, 2024

Recent Insider Transactions by Companies or Individuals for Eyenovia, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.